Infectious Diseases

Combating infectious diseases with next-generation antimicrobial and antiviral therapies

Antimicrobial Innovation

Oracle BioTech develops novel antimicrobial agents to combat resistant pathogens and emerging infectious diseases, addressing critical unmet medical needs in global health.

Antimicrobial Research

Antimicrobial Resistance

Novel antibiotics and combination therapies targeting multidrug-resistant bacteria and emerging resistant pathogens.

  • Novel mechanism antibiotics
  • β-lactamase inhibitors
  • Antibiotic stewardship tools
  • Rapid resistance diagnostics
Learn More
Antiviral Research

Antiviral Therapies

Broad-spectrum antivirals and targeted therapies for emerging viral threats and pandemic preparedness.

  • Broad-spectrum antivirals
  • Respiratory virus treatments
  • Pandemic preparedness
  • Viral resistance monitoring
Learn More

Infectious Disease Pipeline

Discovery

8 Programs

Novel antimicrobial targets and mechanisms.

Preclinical

6 Programs

Pathogen models and resistance studies.

Phase I

4 Programs

Safety studies in healthy volunteers.

Phase II

3 Programs

Efficacy studies in infected patients.

Phase III

1 Program

Pivotal trial for novel antibiotic.